Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 2
1952 2
1953 3
1954 1
1955 1
1956 1
1959 1
1960 2
1961 2
1962 2
1964 2
1965 2
1966 1
1967 1
1968 2
1969 3
1970 5
1971 8
1972 1
1973 3
1974 10
1975 13
1976 4
1977 4
1978 7
1979 8
1980 8
1981 11
1982 19
1983 19
1984 17
1985 17
1986 20
1987 22
1988 21
1989 23
1990 17
1991 17
1992 45
1993 48
1994 39
1995 36
1996 59
1997 49
1998 38
1999 44
2000 51
2001 53
2002 60
2003 58
2004 82
2005 70
2006 80
2007 73
2008 66
2009 78
2010 85
2011 77
2012 93
2013 92
2014 87
2015 91
2016 85
2017 78
2018 80
2019 74
2020 116
2021 117
2022 111
2023 98
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

2,423 results

Results by year

Filters applied: . Clear all
Page 1
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Lesokhin AM, et al. Among authors: yokoyama h. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. Nat Med. 2023. PMID: 37582952 Free PMC article. Clinical Trial.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. Among authors: yokoyama h. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y. Sugiura I, et al. Among authors: yokoyama h. Blood Adv. 2022 Jan 25;6(2):624-636. doi: 10.1182/bloodadvances.2021004607. Blood Adv. 2022. PMID: 34516628 Free PMC article. Clinical Trial.
Cardiovascular surgery training in Japan.
Tanemoto K, Yokoyama H, Okita Y, Ueda Y, Takamoto S, Yaku H, Bando K, Hashimoto K. Tanemoto K, et al. Among authors: yokoyama h. J Thorac Cardiovasc Surg. 2022 Jan;163(1):166-175.e5. doi: 10.1016/j.jtcvs.2020.12.090. Epub 2020 Dec 26. J Thorac Cardiovasc Surg. 2022. PMID: 33589313 Free article. No abstract available.
Revised equations for estimated GFR from serum creatinine in Japan.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Matsuo S, et al. Among authors: yokoyama h. Am J Kidney Dis. 2009 Jun;53(6):982-92. doi: 10.1053/j.ajkd.2008.12.034. Epub 2009 Apr 1. Am J Kidney Dis. 2009. PMID: 19339088
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H. Ishikawa Y, et al. Among authors: yokoyama h. Blood Adv. 2020 Jan 14;4(1):66-75. doi: 10.1182/bloodadvances.2019000709. Blood Adv. 2020. PMID: 31899799 Free PMC article.
Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).
Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N. Sofue T, et al. Among authors: yokoyama h. PLoS One. 2020 Jul 20;15(7):e0236132. doi: 10.1371/journal.pone.0236132. eCollection 2020. PLoS One. 2020. PMID: 32687544 Free PMC article.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
Tough hydrogels with rapid self-reinforcement.
Liu C, Morimoto N, Jiang L, Kawahara S, Noritomi T, Yokoyama H, Mayumi K, Ito K. Liu C, et al. Among authors: yokoyama h. Science. 2021 Jun 4;372(6546):1078-1081. doi: 10.1126/science.aaz6694. Science. 2021. PMID: 34083486
2,423 results